EP2277051A1 - Verfahren zum nachweis des vorkommens von nierensteinen und/oder entzündungen der ableitenden harnwege - Google Patents
Verfahren zum nachweis des vorkommens von nierensteinen und/oder entzündungen der ableitenden harnwegeInfo
- Publication number
- EP2277051A1 EP2277051A1 EP09741736A EP09741736A EP2277051A1 EP 2277051 A1 EP2277051 A1 EP 2277051A1 EP 09741736 A EP09741736 A EP 09741736A EP 09741736 A EP09741736 A EP 09741736A EP 2277051 A1 EP2277051 A1 EP 2277051A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- detection
- urine
- tff2
- urinary tract
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/345—Urinary calculi
Definitions
- a method for detecting the presence of kidney stones and / or inflammations of the urinary tract according to the preamble of the claims. It is suitable for the detection of specific diseases.
- DE 44 44 533 A1 discloses an apparatus and a method for carrying out a test for the detection of particles in the urine (test for determining the susceptibility of a subject for kidney stones).
- DE 38 87 314 T2 discloses a method for detecting basic fetal proteins in urine and a suitable analytical kit.
- DE 18 12 584 discloses a rapid and sensitive detection of bacteria in blood products, urine and other fluids.
- Fucose such as gastric ulcers, liver cirrhosis and carcinomas in humans, are related. This procedure consists in a Comparison of the concentrations of free L-fucose with their normal value in a sample from the subject.
- TFF detection is performed on biopsy-derived cells or in the blood by conventional bioanalytical detection methods, i. it is always necessary to proceed invasively in order to remove cells or blood of the affected patient.
- TFF Plant Factor Fa mily
- TFF1 5 TFF2 and TFF3 have been described so far.
- the physiological occurrence of TFF1 (former names: pS3, BCEI, pNR-2, pNR-105) and TFF2 is mainly confined to the stomach, whereas TFF3 (formerly called Intestinal Trefoil Factor / TTF, hPl.B) is restricted to many mucous Epithelia is synthesized.
- TFF2 (formerly known as pancreatic spasmolytic polypeptides / PSP, spasmolytic polypeptides / SP, human spasmolytic polypeptides / hSP) is a component of gastric juice and occurs in both a glycosylated and a non-glycosylated form.
- gastric TFF2 is bound to muzzine (Kouznetsova et al., (2007) Cell Physiol Biochem 20: 899-908).
- TFF3 Overexpression of TFF3 is known to be associated with prostate cancer.
- TFF peptides are present only in very low concentrations.
- TFF1 nor TFF2 nor TFF3 can be detected by Western blot analysis.
- the invention has for its object to provide a method for the detection of diseases of the urinary tract, which is non-invasively feasible and thereby relatively quickly and inexpensively first hints, for. with regard to the presence of kidney stones and / or inflammation (e.g., after UTI) of the urinary tract, in order to prevent u.a. To clarify caused by inflammation microhematuria quickly and inexpensively.
- TFF2 (and to a lesser extent TFF1 and sometimes also TFF3) is present in urine of kidney stone carriers and patients with UTIs in a significantly increased concentration compared to healthy individuals and is detectable.
- the TFF2 concentration in HWI patients is increased compared to kidney stone carriers, making differential diagnosis possible.
- TFF2 quantitative fluorescent FF2
- ECL system chemiluminescence
- TFF2 A corresponding immunoassay for TFF2 is known in the art (Vestergaard et al., (2004) Scand. J Clin. Lab., Invest., 64: 146-156).
- the advantage of the biochemical method according to the invention is that it represents a cost-effective rapid test, the results of which provide a basis for decision with regard to possibly further required applications / examinations, which are often expensive and stressful for the patient. This is an economic use of z.Z. limited financial resources in the health sector, while at the same time avoiding unnecessary and stressful examinations.
- 1 volume (eg 500 ⁇ L) of a urine sample (eg morning midstream urine) of a patient with suspected UTI is mixed with 4 volumes (eg 2000 ⁇ L) of cold acetone (-2O 0 C) and the proteins precipitated at -20 0 C for at least 2 hours , Then the precipitated proteins are centrifuged for 10 minutes at 4 ° C and 12,000xg. The supernatant is discarded; the pellet is air-dried and then taken up in 0.5% SDS (in half of the original urine volume, eg in 250 ⁇ L).
- the proteins are transferred to a nitrocellulose membrane, fixed with 0.1% glutaraldehyde and counterstained in PBS with an affinity purified polyclonal antiserum
- TFF2 e.g., anti-hTFF2-I, Jagla W, Wiede A, Dietzmann K, Rutkowski
- TFF2 forms are evaluated separately.
- the calibration can be done via recombinant TFF2.
- Significantly increased TFF2 values compared to the control values of healthy persons are an indication of an inflammation, eg by UTI. 2nd embodiment
- TFF2 concentration may also be a differential diagnosis to distinguish HWI or kidney stones.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008022609A DE102008022609B4 (de) | 2008-05-05 | 2008-05-05 | Verfahren zum Nachweis des Vorkommens von Nierensteinen und/oder Entzündungen der ableitenden Harnwege |
PCT/DE2009/000593 WO2009135463A1 (de) | 2008-05-05 | 2009-04-28 | Verfahren zum nachweis des vorkommens von nierensteinen und/oder entzündungen der ableitenden harnwege |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2277051A1 true EP2277051A1 (de) | 2011-01-26 |
Family
ID=41057763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09741736A Ceased EP2277051A1 (de) | 2008-05-05 | 2009-04-28 | Verfahren zum nachweis des vorkommens von nierensteinen und/oder entzündungen der ableitenden harnwege |
Country Status (4)
Country | Link |
---|---|
US (1) | US20110117583A1 (de) |
EP (1) | EP2277051A1 (de) |
DE (1) | DE102008022609B4 (de) |
WO (1) | WO2009135463A1 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110065598A1 (en) * | 2009-08-07 | 2011-03-17 | Rules-Based Medicine, Inc. | Methods and Devices for Detecting Diabetic Nephropathy and Associated Disorders |
EP2661620A4 (de) * | 2011-01-08 | 2014-07-16 | Astute Medical Inc | Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526753A (en) * | 1983-07-06 | 1985-07-02 | Miles Laboratories, Inc. | Multiple profile reagent card |
WO1989001163A1 (en) | 1987-07-24 | 1989-02-09 | Nippon Kayaku Kabushiki Kaisha | Method for assaying basic fetal protein in urine and assaying kit therefor |
JP2613085B2 (ja) * | 1987-11-19 | 1997-05-21 | 寳酒造 株式会社 | L−フコース代謝異常を伴う疾病の検出方法 |
US5464777A (en) | 1994-09-26 | 1995-11-07 | Miles Inc. | Dry reagent for creatinine assay |
DE4444533C2 (de) | 1994-12-14 | 1997-06-12 | Juergen Lehmann | Teststreifen zur Bestimmung von anorganischen Elektrolyten im Urin |
FR2732115B1 (fr) | 1995-03-24 | 1997-06-13 | Immunotech Sa | Procede de dosage immunologique du cortisol, notamment urinaire, et reactifs utilises |
JP5435529B2 (ja) * | 2005-09-02 | 2014-03-05 | 東レ株式会社 | 腎ガン診断、腎ガン患者予後予測のための組成物および方法 |
WO2007110230A2 (en) * | 2006-03-27 | 2007-10-04 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
WO2008005375A2 (en) * | 2006-06-30 | 2008-01-10 | Merck & Co., Inc. | Kidney toxicity biomarkers |
-
2008
- 2008-05-05 DE DE102008022609A patent/DE102008022609B4/de not_active Expired - Fee Related
-
2009
- 2009-04-28 WO PCT/DE2009/000593 patent/WO2009135463A1/de active Application Filing
- 2009-04-28 US US12/991,344 patent/US20110117583A1/en not_active Abandoned
- 2009-04-28 EP EP09741736A patent/EP2277051A1/de not_active Ceased
Non-Patent Citations (1)
Title |
---|
See references of WO2009135463A1 * |
Also Published As
Publication number | Publication date |
---|---|
DE102008022609A1 (de) | 2009-11-19 |
US20110117583A1 (en) | 2011-05-19 |
WO2009135463A1 (de) | 2009-11-12 |
DE102008022609B4 (de) | 2011-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1363128B1 (de) | Diagnose von Myokardinfarkt und akutem Koronarsyndrom durch Kombination von Markern | |
Son et al. | Comparison of serum and urinary nephrin levels between normal pregnancies and severe preeclampsia | |
Sokół et al. | HMGB1 level in cerebrospinal fluid as a marker of treatment outcome in patients with acute hydrocephalus following aneurysmal subarachnoid hemorrhage | |
CN107636468A (zh) | 用于预测认知退化的风险的方法 | |
Norman et al. | The dexamethasone suppression test and completed suicide | |
DE60129314T2 (de) | Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen | |
JP6509201B2 (ja) | 神経変性疾患に関連する方法及び組成物 | |
HUE025796T2 (hu) | Diabéteszes nefropátiához kapcsolt vizelet és szérum biomarkerek | |
EP2081023A3 (de) | Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen | |
EP2442105B1 (de) | Testverfahren für Nierenerkrankungen | |
EP2171465B1 (de) | Lösliches cadherin 17 für die diagnose und risikostratifizierung von krebs und tumor des gastrointestinaltraktes | |
DE102008022609B4 (de) | Verfahren zum Nachweis des Vorkommens von Nierensteinen und/oder Entzündungen der ableitenden Harnwege | |
EP2478377A2 (de) | Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen | |
EP1711831B1 (de) | Diagnose von sepsis durch selektive bestimmung der konzentration der cu/zn superoxiddismutase (cu/zn sod) in patientenproben | |
WO2001014885A2 (de) | Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay | |
US11181523B2 (en) | Method for the early detection of acute kidney injury in critical patients, using fibroblast growth factor 23, klotho and erythropoietin as biomarkers | |
EP0267355A1 (de) | Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine | |
WO2012041494A1 (de) | Differenzialdiagnostik von pankreasadenomen | |
DE602006000603T2 (de) | Verfahren zur Beurteilung von Nephropathia diabetica | |
WO2011121075A1 (de) | VERWENDUNG DER BIOMARKER sFlt UND PIGF IN DER DIAGNOSE UND THERAPIE DER PULMONALEN HYPERTONIE | |
DE602004013142T2 (de) | Verfahren zur Diagnose von Leberfibrose | |
WO2024075844A1 (ja) | 炎症性皮膚疾患の検出及び重症度の判定方法 | |
EP2979094B1 (de) | Verfahren zur diagnose von neuromyelitis optica | |
Badran et al. | Netrin-1 and 8-Hydroxy-2-Deoxyguanosine as Predictor Biomarkers for Diabetic Nephropathy in Type 2 Diabetes Mellitus | |
DE69725333T2 (de) | Verfahren zur bestimmung eines erhöhten sterblichkeitsrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20121023 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20130311 |